{"filing":{"accession_number":"0001193125-26-237207","cik":"0001544227","ticker":"TPST","company_name":"Tempest Therapeutics, Inc.","form":"8-K","filing_date":"2026-05-22","report_date":null,"primary_document":"d131489d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526237207/d131489d8k.htm"},"events":[{"id":10598,"run_id":9298,"accession_number":"0001193125-26-237207","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"Tempest Therapeutics received a deficiency letter from Nasdaq on May 19, 2026, notifying the company it failed to meet the minimum stockholders' equity requirement of $2.5 million (the company reported only $822,000 as of March 31, 2026). Additionally, on May 22, 2026, the company received notice of non-compliance with multiple Nasdaq board composition rules due to director resignations. The company has 45 days to submit a compliance plan and faces potential delisting if it cannot regain compliance within the extended 180-day cure period. This is a clear delisting risk disclosure under Item 3.01.","company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","filing_date":"2026-05-22","submitted_at":null,"items":[{"id":6950,"accession_number":"0001193125-26-237207","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"Tempest Therapeutics received a deficiency letter from Nasdaq on May 19, 2026, notifying the company it failed to meet the minimum stockholders' equity requirement of $2.5 million (the company reported only $822,000 as of March 31, 2026). Additionally, on May 22, 2026, the company received notice of non-compliance with multiple Nasdaq board composition rules due to director resignations. The company has 45 days to submit a compliance plan and faces potential delisting if it cannot regain compliance within the extended 180-day cure period. This is a clear delisting risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:51:13.632587+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6950,"accession_number":"0001193125-26-237207","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"Tempest Therapeutics received a deficiency letter from Nasdaq on May 19, 2026, notifying the company it failed to meet the minimum stockholders' equity requirement of $2.5 million (the company reported only $822,000 as of March 31, 2026). Additionally, on May 22, 2026, the company received notice of non-compliance with multiple Nasdaq board composition rules due to director resignations. The company has 45 days to submit a compliance plan and faces potential delisting if it cannot regain compliance within the extended 180-day cure period. This is a clear delisting risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:51:13.632587+00:00","company_name":"Tempest Therapeutics, Inc.","ticker":"TPST","filing_date":"2026-05-22"}]}